Drugs / Acellular Dermal Matrix
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03057730 | Aug 2015 → Sep 2025 overdue | gingival recession | Tufts University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02450383 | Jan 2015 → Sep 2016 | periodontal disorder, tooth disorder | University of Iowa | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acellular Dermal Matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03057730 ↗ |
| Modality | Other / unclassified | “ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.” NCT03057730 ↗ |
| Route | Other | “The ADM will be placed beneath the flap.” NCT03057730 ↗ |